SCHEMBL17251595

SCHEMBL17251595

COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1N/C=C\C(=O)c1ccc(C)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 3/20 0.67
▸ CA2 P00918 3/20 0.67
▸ NPC1 O15118 2/20 0.57
▸ RAB9A P51151 2/20 0.57
▸ MAPT P10636 2/20 0.57
▸ GAA P10253 1/20 0.57
▸ CXCL12 P48061 1/20 0.55
▸ KRAS P01116 6/20 0.54
▸ TUBB4A P04350 1/20 0.53
▸ TUBB P07437 1/20 0.53
▸ TUBA3C P0DPH7 1/20 0.53
▸ TUBA1B P68363 1/20 0.53
▸ TUBA4A P68366 1/20 0.53
▸ TUBB4B P68371 1/20 0.53
▸ TUBB3 Q13509 1/20 0.53
▸ TUBB2A Q13885 1/20 0.53
▸ TUBB8 Q3ZCM7 1/20 0.53
▸ TUBA3E Q6PEY2 1/20 0.53
▸ TUBA1A Q71U36 1/20 0.53
▸ TUBA1C Q9BQE3 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17251596 0.92 CA1 (0.71) CA1CA2NPC1RAB9AMAPT
SCHEMBL17237391 0.91 BACE1 (0.56) CA1CA2NPC1RAB9AMAPT
SCHEMBL17237394 0.91 BACE1 (0.56) CA1CA2NPC1RAB9AMAPT
SCHEMBL17244223 0.91 KRAS (0.67) CA1CA2NPC1RAB9AMAPT
SCHEMBL17236833 0.91 ABCG2 (0.60) NPC1RAB9AGAAKRASTUBB4A
SCHEMBL17236830 0.91 ABCG2 (0.60) NPC1RAB9AGAAKRASTUBB4A
SCHEMBL17237172 0.90 KRAS (0.67) CA1CA2NPC1RAB9ACXCL12
SCHEMBL20007342 0.90 MEN1 (0.55) CA1CA2NPC1RAB9AKRAS
SCHEMBL17236936 0.90 CXCL12 (0.56) CA1CA2NPC1RAB9AMAPT
SCHEMBL17237347 0.90 KRAS (0.67) CA1CA2NPC1RAB9AKRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487482-B2 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-11-08 — — US disclosed
US-20150322009-A1 NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-11-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322009-A1 NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS MCL1, HCCS, CASP3 CA1 4408/4885CA2 4130/4885NPC1 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback